4119-48-6

Usage

Common Use

Reagent for the detection of aldehydes and ketones in biochemical and pharmaceutical research

Physical State

Yellow crystalline solid

Odor

Strong

Form

Typically used in the form of its hydrochloride salt

Analytical Chemistry

Known for its ability to form a colored complex with aldehydes and ketones

Potential Use

Investigated for its potential use in the treatment of certain types of cancer due to its ability to inhibit the growth of tumor cells

Toxicity

Classified as toxic

Safety Precautions

May cause skin and eye irritation upon contact, should be handled with care

Upstream product

• 108-00-9 N,N-dimethylethylenediamine 
• 97-00-7 1-chloro-2,4-dinitro-benzene 

Downstream Products

• 56756-68-4 N⁽¹⁾-(2-(dimethylamino)ethyl)-4-nitrobenzene-1,2-diamine 
• 925216-52-0 N-(1-(2-(dimethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)thiophen-2-carboximidamide 
• 925216-50-8 N-(2-(2-(dimethylamino)ethylamino)-5-nitrophenyl)acetamide 
• 23251-46-9 C₁₆H₂₉N₅O₄⁽²⁺⁾*2Br^(1-) 

Relevant academic research and scientific papers

Perturbation of the PET process in fluorophore-spacer-receptor systems through structural modification: Transition metal induced fluorescence enhancement and selectivity

Several fluorescent signaling systems are built in the format fluorophore-spacer-receptor with ethylenediamine or N,N-dimethylethylenediamine as the receptor, anthracene as the fluorophore, and a methylene group as the spacer. The receptors are derivatize

NOpiates: Novel dual action neuronal nitric oxide synthase inhibitors with μ-opioid agonist activity

A novel series of benzimidazole designed multiple ligands (DMLs) with activity at the neuronal nitric oxide synthase (nNOS) enzyme and the μ-opioid receptor was developed. Targeting of the structurally dissimilar heme-containing enzyme and the μ-opioid GPCR was predicated on the modulatory role of nitric oxide on μ-opioid receptor function. Structure-activity relationship studies yielded lead compound 24 with excellent nNOS inhibitory activity (IC50 = 0.44 μM), selectivity over both endothelial nitric oxide synthase (10-fold) and inducible nitric oxide synthase (125-fold), and potent μ-opioid binding affinity, Ki = 5.4 nM. The functional activity as measured in the cyclic adenosine monosphospate secondary messenger assay resulted in full agonist activity (EC50 = 0.34 μM). This work represents a novel approach in the development of new analgesics for the treatment of pain.

Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity

The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu-opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain.

Substituted indolines which inhibit receptor tyrosine kinases

Indolinones of the formula having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxycarbonyl-2-indolinone.